Seeking Alpha

Conatus Pharmaceuticals initiates Phase II studies of its alcoholic hepatitis treatment Emricasan

Conatus Pharmaceuticals (CNAT) says it's initiated dosing in Phase II clinical studies of Emricasan in patients with severe alcoholic hepatitis.

The study is designed to assess whether Emricasan improves the 28-day survival in patients with chronic liver disease caused by alcohol and contraindicated to receive corticosteroid therapy for their alcoholic hepatitis.

It's being conducted by the Translational Research and Evolving Alcoholic Hepatitis Treatment Consortium consisting of the Mayo Clinic Rochester, Indiana University, and Virginia Commonwealth University in collaboration with the National Institute on Alcohol Abuse and Alcoholism.

Shares +0.5% AH.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs